Clinical & Translational Oncology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2024-11-16 ms1000001788822136 来自上海

8.04 revision submitted
8.09 editor assigned
8.09 accept
编辑停给力点，一审用了20多天，修回5条意见
二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍

23 0

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2024-11-14 ms8000001793522662 来自湖北省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤;综述;免疫检查点抑制剂
经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助
具体的投稿进度：8.2 submitted to journal
8.3 editor assigned
8.6 with editor
8.8 Under review
10.7 minor revision
要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2023-07-31 脸圆环奈来自湖北省

偏重的研究方向：肿瘤;癌症;基础
经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志

109 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2023-03-22 1205960dm93(暂无昵称) 来自上海

请问reviewer assigned需要多久啊？已经等了半个月了

119 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2023-10-30 P拾荒者来自浙江省

偏重的研究方向：癌症;临床;预后标志物
经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果

123 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2022-11-23 若素9442

偏重的研究方向：乳腺癌;肿瘤
经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯

141 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2023-12-10 ms6000001228150935 来自河南省

审稿速度:1.0
经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject

129 0

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2023-06-05 1defbc5bm21(暂无匿称) 来自浙江省

审稿速度:3.0 | 投稿命中率:95.0
偏重的研究方向：肺癌;基础
经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。
总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。

14 Feb 2023 submit
19 Feb 2023 Editor Invited
26 Feb 2023 Under review
08 Apr 2023 Reviews Completed
12 Apr 2023 Reviews Completed
20 Apr 2023 Reviews Completed
22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页）
11 May 2023 submit revision R1
15 May 2023 Editor Assigned
16 May 2023 Major revisions
17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit
18 May 2023 Editor Assigned
20 May 2023 Accept
26 May 2023 版权协议
27 May 2023 proof
30 May 2023 online

132 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2023-06-30 lichichi1949 来自四川省

审稿速度:1.0 | 投稿命中率:50.0
经验分享：无理由秒拒

127 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2237322, encodeId=6c9e223e3222c, content=8.04 revision submitted 8.09 editor assigned 8.09 accept 编辑停给力点，一审用了20多天，修回5条意见 二审提交到编辑那儿用了7天（有惊无险）编辑当天审核并且通过了，点赞👍 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=520e8539624, createdName=ms1000001788822136, createdTime=Sat Nov 16 23:49:52 CST 2024, time=2024-11-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2236900, encodeId=5fcd223690076, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤;综述;免疫检查点抑制剂 经验分享：必须要夸一夸期刊的审稿速度，整个过程都非常丝滑（除了系统里面不能像爱思唯尔一样实时跟进审稿进度导致有点焦虑），不过事实证明，期刊审稿人真的非常负责!每一步都超级快，非常适合毕业年级。本来投搞的时候没有抱着能靠这个毕业的心态，因此还投稿了一篇中文，然而事实证明这个比中文还要快。不过由于期刊发文量不算多，感觉稿件还是得认真对待，尽量把格式等问题都搞好吧，成功概率会大一些。之前投稿的时候从大家的经验中也得到了很多有用的信息，所以现在自己也来分享了，希望对接下来想投稿的人有一些帮助 具体的投稿进度：8.2 submitted to journal 8.3 editor assigned 8.6 with editor 8.8 Under review 10.7 minor revision 要求返修的截止日期给到了12.30，其实返修意见不多，也并不难改，不过由于自己非常拖延，一直到了11.12号才提交返修稿，然后11.13号 editor assigned，11.14号就直接接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=605c5570793, createdName=ms8000001793522662, createdTime=Thu Nov 14 12:43:37 CST 2024, time=2024-11-14, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2150645, encodeId=eca9215064565, content=偏重的研究方向：肿瘤;癌症;基础 经验分享：分享投稿流程希望可以帮助投稿的小伙伴们 6月7日投稿 6月8日修改参考文献格式重新提交 6月10日分配编辑 6月12日审稿人邀请审稿人同意 7月21日小修审稿人意见很友好只修改了两处文章标注错误回答了审稿人两个小问题 7月22日返回修改稿 7月23日接收审稿时发过两次邮件催稿得到的都是编辑助理回复的文章在审有消息第一时间通知编辑处理文章非常快回复邮件也很快效率非常高的杂志, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=109, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e178390071, createdName=脸圆环奈, createdTime=Mon Jul 31 16:51:40 CST 2023, time=2023-07-31, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2121134, encodeId=69ca2121134a4, content=请问reviewer assigned需要多久啊？已经等了半个月了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=119, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2b3b2173627, createdName=1205960dm93(暂无昵称), createdTime=Wed Mar 22 16:16:05 CST 2023, time=2023-03-22, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2165794, encodeId=4ac12165e9439, content=偏重的研究方向：癌症;临床;预后标志物 经验分享：记录一下过程吧。 10.24提交 10.28 reviewer assigned 10.30 under review 希望有个好结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Mon Oct 30 20:47:40 CST 2023, time=2023-10-30, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2102231, encodeId=5f1321022311d, content=偏重的研究方向：乳腺癌;肿瘤 经验分享：10.18投稿10.25送外审11.21外审意见回来小修11.22修回11.23接受，效率很快，提出的意见也很中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Wed Nov 23 19:49:41 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2174151, encodeId=e06f21e41510a, content=审稿速度:1.0 经验分享：Nov.3 submission Nov.4 Editor assigned-reviewers assigned Nov.12 日期更新reviewers assigned Nov.14 under review Nov.15 reviewers assigned Nov.30 reviewers assigned Dec.04 reject, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=794c9103199, createdName=ms6000001228150935, createdTime=Sun Dec 10 23:53:27 CST 2023, time=2023-12-10, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140919, encodeId=690f214091946, content=审稿速度:3.0 | 投稿命中率:95.0 偏重的研究方向：肺癌;基础 经验分享：终于结束，就这样！一审审稿比较慢，2个多月，等的有点着急。大修给的截止日期本来是7月份，但因为审稿意见中真正的实验只有一个需要补充，所以修回的比较快，但4个评审意见真是回复到崩溃，太多了。还好四个评审意见都偏积极，我们回复的也够充分，基本都是正面直接回答的。 总结：偏临床型杂志，审稿人感觉临床医生居多，所以没有提很多机制性问题，大多问题都跟临床有关。 14 Feb 2023 submit 19 Feb 2023 Editor Invited 26 Feb 2023 Under review 08 Apr 2023 Reviews Completed 12 Apr 2023 Reviews Completed 20 Apr 2023 Reviews Completed 22 Apr 2023 Major revisions（4个审稿意见，回复意见写了19页） 11 May 2023 submit revision R1 15 May 2023 Editor Assigned 16 May 2023 Major revisions 17 May 2023 submit revision R2 又收到了一模一样的大修邮件。沟通后又重新submit 18 May 2023 Editor Assigned 20 May 2023 Accept 26 May 2023 版权协议 27 May 2023 proof 30 May 2023 online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=631e1736149, createdName=1defbc5bm21(暂无匿称), createdTime=Mon Jun 05 16:54:14 CST 2023, time=2023-06-05, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2145669, encodeId=3f6d2145669f2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：无理由秒拒, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263e1426598, createdName=lichichi1949, createdTime=Fri Jun 30 16:02:30 CST 2023, time=2023-06-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2101371, encodeId=6ad721013e159, content=偏重的研究方向：肿瘤 经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIBIaVXAjmGbWDnIwUczEXEaeRiasW0G2JL6GgskzOwsfR6ttH6ef4da1VeA6MHtyT9y1LCMMm2lCA/132, createdBy=2bb25254374, createdName=若素9442, createdTime=Fri Nov 18 18:25:04 CST 2022, time=2022-11-18, status=1, ipAttribution=)]

2022-11-18 若素9442

偏重的研究方向：肿瘤
经验分享：大佬们under review了一个月昨天又变成Editor Assigned什么意思啊。。这是送了外审没呀

108 9

展开9条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务